SuppreMol obtains license for RA antibody from the University Hospital Regensburg

27-Jul-2012 - The Bayerische Patentallianz GmbH licences an antibody directed against interleukin 3 (IL-3), which has been generated at the University Hospital Regensburg, to SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases. ...

SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials

Data confirm excellent safety profile and therapeutic activity

16-Feb-2012 - SuppreMol GmbH announced interim results of the Phase Ib/IIa clinical trial of SM101 to treat Primary Immune Thrombocytopenia (ITP). SM101 was safe and very well tolerated with encouraging efficacy data.The Phase Ib section of this randomized, double-blind, placebo-controlled, dose escalating, ...

SuppreMol Receives Orphan Drug Designation for SM101

14-Sep-2007 - SuppreMol GmbH announced that the European Commission has granted orphan medicinal product designation for Suppre- Mol's lead product SM101, a recombinant human soluble Fc-gamma receptor IIb, for the treatment of idiopathic thrombocytopenic purpurea (ITP). SM101 is in preclinical development and ...

SuppreMol launched as a new company

30-Nov-2005 - Z-Cube, the corporate venture capital arm of the Zambon Group took another important step forwards in fostering pharmaceutical innovation, signing a contract to provide finance and expert support to SuppreMol GmbH. This marked the project's official launch as a new company after several years of ...